Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696.

about

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696.

Item

http://www.wikidata.org/entity/Q36405279

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696.

@ast

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696.

@en

type

Item

label

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696.

@ast

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696.

@en

prefLabel

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696.

@ast

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696.

@en

P1476

Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696.

@en

P2093

Bin Meng

http://www.w3.org/2001/XMLSchema#string

Bo Li

http://www.w3.org/2001/XMLSchema#string

Bo Yin

http://www.w3.org/2001/XMLSchema#string

Feng Chen

http://www.w3.org/2001/XMLSchema#string

Fengshuang An

http://www.w3.org/2001/XMLSchema#string

Hongxia Zhang

http://www.w3.org/2001/XMLSchema#string

Hui Sun

http://www.w3.org/2001/XMLSchema#string

Mengfei Helian

http://www.w3.org/2001/XMLSchema#string

Xinmei Wang

http://www.w3.org/2001/XMLSchema#string

Yunhe Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis in clinical trials

Angiotensin-neprilysin inhibition versus enalapril in heart failure

Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

Quantitative methods in the review of epidemiologic literature.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribut

Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction.

The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis.

Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.

P31

scholarly article

P356

10.18632/ONCOTARGET.18312

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28614052

http://www.w3.org/2001/XMLSchema#string

29137346

http://www.w3.org/2001/XMLSchema#string

P932

5669972

http://www.w3.org/2001/XMLSchema#string